Eisai presentations at the Annual Meeting of the American Epilepsy Society (AES) included key data on long-term convulsive seizure-freedom rates of adjunctive perampanel (marketed as FYCOMPA® CIII) in adolescent patients, monotherapy in partial-onse

WOODCLIFF LAKE, N.J., Dec. 6, 2017 /PRNewswire/ — Eisai Inc. presented eight posters on perampanel (marketed as FYCOMPA® CIII) at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C. The poster presentations included analyses of convulsive seizure-freedom rates,…